In light of FDA IND acceptance for NBI-1117567, a milestone of USD 10 million will be received from Neuroklin. Nexera Pharma retains development and commercialization rights for M1 receptor agonists in Japan. Revenue is expected to be recorded in the third quarter of fiscal year 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nexera Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-26","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4565-20260826-01.pdf","jir_short_summary":"In light of FDA IND acceptance for NBI-1117567, a milestone of USD 10 million will be received from Neuroklin. Nexera Pharma retains development and commercialization rights for M1 receptor agonists in Japan. Revenue is expected to be recorded in the third quarter of fiscal year 2026.","jir_summary":"### Section Heading\nAcquisition of milestones based on IND acceptance for NBI-1117567 by partner Neuroklin and the financial impact of this matter. Description of the development status of the muscarinic receptor agonist class under the NxWave platform and the handling of development and commercialization rights in the Japanese market.\n\n### Section 2 Heading\nCommentary on future pipeline progress and market opportunities, Japan and global development cost burden structure, and long-term monetization outlook. It notes that the short-term financial impact of IND acceptance is already incorporated in FY2026 Q3 revenue.","jir_financial_highlights":"Milestone receipt amount: 10 \u767e\u4e07\u7c73\u30c9\u30eb\nTiming of revenue recognition: FY2026 Q3","jir_category":"","jir_hashtags":"#NexeraPharma, #Partnership, #MuscarinicReceptorAgonist","jir_key_figures":"Milestone receipt amount: 10 \u767e\u4e07\u7c73\u30c9\u30eb\nTiming of revenue recognition: FY2026 Q3\nDevelopment and commercialization rights: Japan\u2014holding development and commercialization rights for muscarinic M1 receptor agonists","jir_meta_title":"\u3010NexeraPharma\u3011IND Acceptance with Partner and Milestone Event\uff5cAugust 2026","jir_meta_description":"Reports IND acceptance and milestone receipt for NI-1117567 in relation to the partnership between NexeraPharma and Neuroklin. While retaining development and commercialization rights in Japan, revenue is expected to be recognized in FY2026 Q3.","jir_og_title":"\u3010NexeraPharma\u3011Notice of IND Acceptance and Milestone Event","jir_og_description":"Summary of IND acceptance for Neuroklin's NBI-1117567 and the USD 10 million milestone. Includes future development prospects.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-107363","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n